Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.
The rapid growth of Saudi Arabia’s pharmaceutical market will be placed under the spotlight at the forthcoming CPHI Middle East and Africa event, as the latest industry data reveals the Kingdom’s pharmaceutical market is expected to be valued at $10.74 billion (SR40.1 billion) by 2023.
The event, sponsored by the Ministry of Health and Prevention (MoHaP), returns to the Abu Dhabi National Exhibition Center (ADNEC) from Sept. 16-18 and will explore the rapid reform of the country’s healthcare system at both regulatory and service provision levels, in line with Saudi Arabia’s Vision 2030 and the National Transformation Program.
According to the latest IQVIA Market Prognosis — Saudi Arabia report, the Kingdom’s pharmaceutical market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% until 2023.
Cara Turner, Brand Director — Pharma, Informa Markets, the organizers of the event, said: “Saudi Arabia is one of the largest pharmaceutical markets in the Middle East, and its expansion over recent years can be attributed to a growing population, an increase in non-communicable diseases and strong state support for health services, with major government investment in new hospitals and clinics.”
According to UN figures, Saudi Arabia’s population stands at an estimated 34 million, 32% of which are under 14 years and is growing at around 2% annually. Life expectancy has increased from 69 years in 1990 to over 75 years today.
Saudi Arabia covers 2.15 million sq. km and Riyadh and Jeddah are home to 6.5 and four million residents respectively, almost a third of the entire population, creating their own unique healthcare dynamics. This is in sharp contrast to over 12 million Saudis who live in isolated or sparsely populated areas, challenging consistent healthcare delivery.
“Putting that into perspective, geographically Saudi Arabia is the 12th largest country in the world, but in terms of population density, it is ranked 209,” said Turner.
In addition, the rise in non-communicable diseases such as cardiovascular diseases, cancer, chronic respiratory disease, diabetes and obesity, which tend to require long-term treatment and medication. Many of these diseases are a consequence of poor lifestyle choices, but alarmingly over 35,000 children have been diagnoses with Type 1 diabetes placing the Kingdom in the top four countries worldwide in terms of incidence.
“To address these issues, in 2019 alone, the Saudi government introduced a 17% increase ($45.86 billion) in funds allocated for spending on health and social development — with approximately $12.72 billion earmarked for spending on healthcare projects directly linked to Saudi’s Vision 2030,” added Turner.
At present pharmaceuticals manufactured overseas continue to account for the majority of the market – with around just 20% of the drugs consumed in the country made locally. The government, conscious of the growing costs of imported pharmaceuticals, along with the MoH and other health service providers has implemented long-term development strategies in a bid to promote local medicines.
Turner said: “Under the National Transformation Programme (NTP), the kingdom is working to boost the proportion of local manufacturing in the pharma-sector to approximately 40% by the end of 2020. While, the Ministry of Health (MoH) has been tasked with further localising the industry, both in terms of sources and in employment.”
“A price protection strategy for locally-produced products - such as exemptions from price cuts imposed during the re-registration process – is just one of the tools being used to attract further investment in the Saudi pharmaceutical sector in line with Vision 2030 and as an incentive for further stimulating local manufacturing in the region,” Turner added.
CPHI Middle East & Africa is the region’s leading platform that brings together pharma ingredients, product manufacturers, suppliers and buyers covering every step of the pharma supply chain from drug research and discovery to finished dosage.
The event, which recently signed a Memorandum of Understanding with the Ministry of Health and Prevention (MoHaP) to be lead sponsor and supporting partner, is set to attract attendees from the Middle East and Africa (MEA), the MENA region accounting for 4% of the global pharma market, and the rest of the world.
Over 294 local, regional and international exhibitors from more than 35 countries are expected to attend the three-day showcase. In addition to the global network of exhibitors, the event is expected to attract over 4,900 participants, more than 50% of which will come from the MEA region.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance